Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 401–500 of 1,060

A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial
Nelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c392e · Cited by 230
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score
Albert, M. A., Glynn, R. J., & Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000080289.72166.cf · Cited by 267
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial
Glynn, R. J., Koenig, W., Nordestgaard, B. G., Shepherd, J., & Ridker, P. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-8-201004200-00005 · Cited by 252
Risk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 263
The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol‐lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis
Palinski, W., & Claudio Napoli, A. (2002) · The FASEB Journal · doi:10.1096/fj.02-0226rev · Cited by 272
Primary Prevention of Coronary Heart Disease
Grundy, S. M. (1999) · Circulation · doi:10.1161/01.cir.100.9.988 · Cited by 266
A review of CETP and its relation to atherosclerosis
de Grooth, G. J., Klerkx, A. H. E. M., Stroes, E. S. G., Stalenhoef, A. F. H., Kastelein, J. J. P., & Kuivenhoven, J. A. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400007-jlr200 · Cited by 264
Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial)
Kullo, I. J., Jouni, H., Austin, E. E., Brown, S.-A., Kruisselbrink, T. M., Isseh, I. N., Haddad, R. A., Marroush, T. S., Shameer, K., Olson, J. E., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.020109 · Cited by 267
A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study
Clarke, S., Kelleher, J., Lloyd‐Jones, H., Slack, M. C., & Schofield, P. M. (2002) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2002.01544.x · Cited by 267
Beyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 263
Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins
Danaei, G., Tavakkoli, M., & Hernán, M. Á. (2012) · American Journal of Epidemiology · doi:10.1093/aje/kwr301 · Cited by 275
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Reith, C. A., Baigent, C., Blackwell, L. S., Emberson, J., Spata, E., Davies, K., Halls, H. J., Holland, L., Wilson, K., Armitage, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01545-8 · Cited by 301
Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression: Hepatic Lipase–Mediated Changes in LDL Density
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease
Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., Pastore, M., Borrello, F., Belcastro, M., Picchi, A., et al. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00010-x · Cited by 264
Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., McInnes, G. T., Mehlsen, J., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106000-00020 · Cited by 266
Effect of statins on atherosclerotic plaque
Almeida, S. O., & Budoff, M. J. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.01.001 · Cited by 275
Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study.
Austin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., Brunzell, J. D., & Motulsky, A. G. (2000) · Circulation · doi:10.1161/01.cir.101.24.2777 · Cited by 255
Effects of a healthy Nordic diet on cardiovascular risk factors in hypercholesterolaemic subjects: a randomized controlled trial (NORDIET)
Adamsson, V., Reumark, A., Fredriksson, I.-B., Hammarström, E., Vessby, B., Johansson, G., & Risérus, U. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02290.x · Cited by 268
Large Scale Cohort Study of the Relationship Between Serum Cholesterol Concentration and Coronary Events With Low-Dose Simvastatin Therapy in Japanese Patients With Hypercholesterolemia: Primary Prevention Cohort Study of the Japan Lipid Intervention Trial (J-LIT)
Matsuzaki, M., Kita, T., Mabuchi, H., Matsuzawa, Y., Nakaya, N., Oikawa, S., Saito, Y., Sasaki, J., Shimamoto, K., Itakura, H., et al. (2002) · Circulation Journal · doi:10.1253/circj.66.1087 · Cited by 260
Statins are Associated with a Reduced Infrarenal Abdominal Aortic Aneurysm Growth
Schouten, O., van Laanen, J. H. H., Boersma, E. H., Vidaković, R., Feringa, H. H. H., Dunkelgrün, M., Bax, J. J., de Koning, J. J., van Urk, H., & Poldermans, D. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2005.12.024 · Cited by 263
Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities
Rosenson, R. S. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00239-9 · Cited by 264
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty Final results of the fluvastatin angiographic restenosis (FLARE) trial
Serruys, P. W. J. C. (1999) · European Heart Journal · doi:10.1053/euhj.1998.1150 · Cited by 258
Pharmaceutical Care Services and Results in Project ImPACT: Hyperlipidemia
Bluml, B. M., McKenney, J. M., & Cziraky, M. J. (2000) · Journal of the American Pharmaceutical Association (1996) · doi:10.1016/s1086-5802(16)31059-2 · Cited by 258
Total, LDL, and HDL Cholesterol Decrease With Age in Older Men and Women
Ferrara, A. M., Barrett-Connor, E. L., & Shan, J. (1997) · Circulation · doi:10.1161/01.cir.96.1.37 · Cited by 257
Naringin supplementation lowers plasma lipids and enhances erythrocyte antioxidant enzyme activities in hypercholesterolemic subjects
Jung, U. J., Kim, H. J., Lee, J. S., Lee, M. K., Kim, H. O., Park, E. J., Kim, H. J., Jeong, T., & Choi, M. (2003) · Clinical Nutrition · doi:10.1016/s0261-5614(03)00059-1 · Cited by 261
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Pasternak, R. C., Smith, S. C., Merz, C. N. B., Grundy, S. M., Cleeman, J. I., & Lenfant, C. J. M. (2002) · Stroke · doi:10.1161/01.str.0000034125.94759.41 · Cited by 257
High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey
Aguilar-Salinas, C. A., Oláiz, G., Valles, V., Torres, J., Pérez, F. J. G., Rull, J. A., Rojas, R., Franco, A., & Sepúlveda, J. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31581-9 · Cited by 257
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*
Chapman, M. J., Assmann, G., Fruchart, J., Shepherd, J., & Sirtori, C. R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004402 · Cited by 257
Cerivastatin, a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor, Improves Endothelial Function in Elderly Diabetic Patients Within 3 Days
Tsunekawa, T., Hayashi, T., Kano, H., Sumi, D., Matsui‐Hirai, H., Thakur, N. K., Egashira, K., & Iguchi, A. (2001) · Circulation · doi:10.1161/hc2901.094094 · Cited by 256
Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials
Pignone, M. P. (2000) · BMJ · doi:10.1136/bmj.321.7267.983 · Cited by 256
Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial
Kirkpatrick, P. J., Turner, C. L., Smith, C., Hutchinson, P. J., & Murray, G. D. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70084-5 · Cited by 253
Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy
MacMahon, S., Sharpe, N., Gamble, G., Hart, H., Scott, J., Simes, J., & White, H. (1998) · Circulation · doi:10.1161/01.cir.97.18.1784 · Cited by 254
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
The lipid and non-lipid effects of statins
Wierzbicki, A. S., Poston, R. N., & Ferro, A. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(03)00055-x · Cited by 253
Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey
Hobbs, R. F. (2002) · Family Practice · doi:10.1093/fampra/19.6.596 · Cited by 257
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
Ridker, P. M., Genest, J. J., Boekholdt, S. M., Libby, P., Gotto, A. M., Nordestgaard, B. G., Mora, S., MacFadyen, J. G., Glynn, R. J., & Kastelein, J. J. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60713-1 · Cited by 257
Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study.
Mercuri, M., Bond, M., Sirtori, C., Veglia, F., Crepaldi, G., Feruglio, F., Descovich, G., Ricci, G., Rubba, P., Mancini, M., et al. (1996) · American Journal of Medicine · doi:10.1016/s0002-9343(96)00333-6 · Cited by 283
Prevention of Coronary Heart Disease by Diet and Lifestyle
Kromhout, D., Menotti, A., Kesteloot, H., & Sans, S. (2002) · Circulation · doi:10.1161/hc0702.103728 · Cited by 255
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity
Zacco, A., Togo, J. A., Spence, K., Ellis, A., Lloyd, D., Furlong, S., & Piser, T. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-35-11104.2003 · Cited by 255
Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics
Prosser, L. A., Stinnett, A. A., Goldman, P. A., Williams, L. W., Hunink, M. G. M., Goldman, L., & Weinstein, M. C. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00002 · Cited by 249
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease
Lefer, A. M. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00247-9 · Cited by 248
Simvastatin Initiated Early After Heart Transplantation
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Krobot, K. J., Steinbeck, G., Seidel, D., & Reichart, B. (2003) · Circulation · doi:10.1161/01.cir.0000043241.32523.ee · Cited by 246
High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease
Ford, I., Shah, A. S. V., Zhang, R., McAllister, D., Strachan, F. E., CASLAKE, M. J., Newby, D. E., Packard, C. J., & Mills, N. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.020 · Cited by 247
Dietary Fatty Acids and the Regulation of Plasma Low Density Lipoprotein Cholesterol Concentrations ,
Dietschy, J. M. (1998) · Journal of Nutrition · doi:10.1093/jn/128.2.444s · Cited by 247
Coronary Heart Disease in Smokers: Vitamin C Restores Coronary Microcirculatory Function
Kaufmann, P. A., Gnecchi-Ruscone, T., di Terlizzi, M., Schäfers, K. P., Lüscher, T. F., & Camici, P. G. (2000) · Circulation · doi:10.1161/01.cir.102.11.1233 · Cited by 246
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits
Rikitake, Y. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00468-8 · Cited by 246
Statin Adherence and Risk of Accidents
Dormuth, C. R., Patrick, A. R., Shrank, W. H., Wright, J. M., Glynn, R. J., Sutherland, J., & Brookhart, M. A. (2009) · Circulation · doi:10.1161/circulationaha.108.824151 · Cited by 245
Cholesterol-Lowering Effect of a Theaflavin-Enriched Green Tea Extract
Maron, D. J., Lu, G. P., Cai, N. S., Wu, Z. G., Li, Y. H., Chen, H., Zhu, J. Q., Xue, J., Wouters, B. C., & Zhao, J. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.12.1448 · Cited by 246
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
NADPH oxidases in the vasculature: Molecular features, roles in disease and pharmacological inhibition
Selemidis, S., Sobey, C. G., Wingler, K., Schmidt, H. H. H. W., & Drummond, G. R. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.08.005 · Cited by 249
Non-adherence to cardiovascular medications
Kolandaivelu, K., Leiden, B. B., O’Gara, P. T., & Bhatt, D. L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu364 · Cited by 249
Regulation of Bile Acid and Cholesterol Metabolism by PPARs
Li, T., & Chiang, J. Y. L. (2009) · PPAR Research · doi:10.1155/2009/501739 · Cited by 260
Targeting tumor cell metabolism with statins
Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 247
PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
Bruce, I. N., Gladman, D. D., & Urowitz, M. B. (2000) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70138-1 · Cited by 240
Plaque Rupture After Short Periods of Fat Feeding in the Apolipoprotein E–Knockout Mouse
Johnson, J. L., Carson, K. G. S., Williams, H. J., Karanam, S., Newby, A. C., Angelini, G. D., George, S. J., & Jackson, C. L. (2005) · Circulation · doi:10.1161/01.cir.0000158435.98035.8d · Cited by 241
Safety and Tolerability of Pravastatin in Long-Term Clinical Trials
Pfeffer, M. A., KEECH, A. C., Sacks, F. M., Cobbe, S. M., Tonkin, A. M., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 239
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 247
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study
Ford, I., Murray, H., McCowan, C., & Packard, C. J. (2016) · Circulation · doi:10.1161/circulationaha.115.019014 · Cited by 238
Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer
Alsheikh-Ali, A. A. A., Maddukuri, P. V., Han, H., & Karas, R. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.073 · Cited by 243
High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions
Barter, P. J., Kastelein, J. J. P., Nunn, A. V. W., & Hobbs, R. F. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00006-6 · Cited by 242
Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis
Angerer, P., Störk, S., Kothny, W., Schmitt, P., & von Schacky, C. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.2.262 · Cited by 240
Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients
John, S., Schlaich, M. P., Langenfeld, M. R. W., Weihprecht, H., Schmitz, G., Weidinger, G., & Schmieder, R. E. (1998) · Circulation · doi:10.1161/01.cir.98.3.211 · Cited by 237
Effects of calcium supplementation on serum lipid concentrations in normal older women:
Reid, I. R., Mason, B., Horne, A. M., Ames, R. W., Clearwater, J. M., Bava, U., Orr‐Walker, B., Wu, F., Evans, M. C., & Gamble, G. D. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01138-x · Cited by 234
Long-term adherence with cardiovascular drug regimens
Kulkarni, S. P., Alexander, K. P., Lytle, B. L., HEISS, G. M., & Peterson, E. D. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.038 · Cited by 242
Newborn screening for inborn errors of metabolism: a systematic review.
Seymour, Thomason, M. J., Chalmers, Addison, Bain, Cockburn, Littlejohns, Lord, J. L., & Wilcox (1997) · Health Technology Assessment · doi:10.3310/hta1110 · Cited by 254
Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery
Kertai, M. D., Boersma, E. H., Westerhout, C. M., van Domburg, R., Klein, J., Bax, J. J., van Urk, H., & Poldermans, D. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.029 · Cited by 232
Epidemiology of Stroke
Wolf, P. A. (2004) · Elsevier eBooks · doi:10.1016/b0-44-306600-0/50005-5 · Cited by 233
A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression
Kuvin, J. T., Rämet, M. E., Patel, A. R., Pandian, N. G., Mendelsohn, M. E., & Karas, R. H. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123145 · Cited by 233
HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial Cells
Bourcier, T., & Libby, P. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.2.556 · Cited by 233
Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
Hsia, J., MacFadyen, J. G., Monyak, J., & Ridker, P. M. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.082 · Cited by 231
Coronary artery disease in Saudi Arabia
Al-Nozha, M. M., Arafah, M., Al-Mazrou, Y. Y., Al-Maatouq, M. A., Khan, N. B., Khalil, M. Z., Al-Khadra, A. H., Al-Marzouki, K., Abdullah, M., Al-Harthi, S. S., et al. (2004) · Saudi Medical Journal · doi:10.15537/1658-3175.2534 · Cited by 231
Insulin resistance and the endothelium
Hsueh, W. A., Lyon, C. J., & Quiñones, M. J. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.042 · Cited by 236
A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events
Whitney, E. J., Krasuski, R. A., Personius, B. E., Michalek, J. E., Maranian, A. M., Kolasa, M. W., Monick, E. A., Brown, B. G., & Gotto, A. M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-2-200501180-00008 · Cited by 233
High-Density Lipoprotein and Coronary Heart Disease
Natarajan, P., Ray, K. K., & Cannon, C. P. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.008 · Cited by 231
Effect of HMGcoA Reductase Inhibitors on Stroke
Bucher, H. C., Griffith, L. E., & Guyatt, G. H. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00002 · Cited by 229
Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca 2+ signalling and insulin secretion due to blockade of L‐type Ca 2+ channels in rat islet β‐cells
Yada, T., Nakata, M., Shiraishi, T., & Kakei, M. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702397 · Cited by 231
Reduction of Serum Cholesterol in Postmenopausal Women With Previous Myocardial Infarction and Cholesterol Malabsorption Induced by Dietary Sitostanol Ester Margarine
Gylling, H., Radhakrishnan, R., & Miettinen, T. A. (1997) · Circulation · doi:10.1161/01.cir.96.12.4226 · Cited by 228
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Statins and risk of cancer: A systematic review and metaanalysis
Browning, D., & Martin, R. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.22366 · Cited by 228
Metabolic Changes in Persons After Spinal Cord Injury
Bauman, W. A., & Spungen, A. M. (2000) · Physical Medicine and Rehabilitation Clinics of North America · doi:10.1016/s1047-9651(18)30150-5 · Cited by 231
Coronary Heart Disease: Reducing the Risk
Assmann, G., Cullen, P., Jossa, F., Lewis, B., & Mancini, M. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.8.1819 · Cited by 229
Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial
Ouchi, Y., Sasaki, J., Arai, H., Yokote, K., Harada, K., Katayama, Y., Urabe, T., Uchida, Y., Hayashi, M., Yokota, N., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.039415 · Cited by 231
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Liposomes as vehicles for vitamins E and C: An alternative to fortify orange juice and offer vitamin C protection after heat treatment
Marsanasco, M., Márquez, A. L., Wagner, J. R., Alonso, S. D. V., & Chiaramoni, N. S. (2011) · Food Research International · doi:10.1016/j.foodres.2011.07.025 · Cited by 227
Simvastatin Inhibits Leukocyte–Endothelial Cell Interactions and Protects Against Inflammatory Processes in Normocholesterolemic Rats
Pruefer, D., Scalia, R. G., & Lefer, A. M. (1999) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.19.12.2894 · Cited by 225
Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future?
Cooney, M. T., Dudina, A., D'Agostino, R., & Graham, I. M. (2010) · Circulation · doi:10.1161/circulationaha.109.852756 · Cited by 222
Cardiovascular morbidity and mortality after kidney transplantation
Stoumpos, S., Jardine, A. G., & Mark, P. B. (2014) · Transplant International · doi:10.1111/tri.12413 · Cited by 227
Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study
Eagle, K. A., Kline-Rogers, E. M., Goodman, S. G., Gurfinkel, E., Avezum, Á., Flather, M. D., Granger, C. B., Erickson, S. R., White, K., & Steg, P. G. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.041 · Cited by 230
Evidence for Statin Pleiotropy in Humans
Liu, P., Liu, Y.-W., Lin, L.-J., Chen, J.-H., & Liao, J. K. (2008) · Circulation · doi:10.1161/circulationaha.108.813311 · Cited by 224
The Relationship between Lung Inflammation and Cardiovascular Disease
van Eeden, S. F., Leipsic, J. A., Man, S. F. P., & Sin, D. D. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0455pp · Cited by 241
2023 Chinese guideline for lipid management
Li, J., Zhao, S., Zhao, D. H., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 241
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
Lipid parameters for measuring risk of cardiovascular disease
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.223 · Cited by 234
Indicators of Quality in Health Care
Lawrence, M., & Olesen, F. (1997) · European Journal of General Practice · doi:10.3109/13814789709160336 · Cited by 225
A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome
Waksman, R., Torguson, R., Kent, K. M., Pichard, A. D., Suddath, W. O., Satler, L. F., Martin, B. D., Perlman, T. J., Maltais, J. B., Weissman, N. J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.12.067 · Cited by 224
Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia
Beaven, S. W., & Tontonoz, P. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131428 · Cited by 230
Management of hypertriglyceridemia
Simha, V. (2020) · BMJ · doi:10.1136/bmj.m3109 · Cited by 230
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
Cai, T., Abel, L., Langford, O., Monaghan, G., Aronson, J. K., Stevens, R., Lay-Flurrie, S. L., Koshiaris, C., McManus, R. J., Hobbs, R. F., et al. (2021) · BMJ · doi:10.1136/bmj.n1537 · Cited by 237
Clinical Pharmacokinetics of Pravastatin
Hatanaka, T. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039060-00002 · Cited by 225

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks